Learn About Gastroesophageal Junction Cancer

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Gastroesophageal Junction Cancer Local Doctors?
KS
Kohei Shitara
Elite
Highly rated in
12
conditions

National Cancer Center Hospital East

Chiba, JP 

Kohei Shitara is in Chiba, Japan. Shitara is rated as an Elite expert by MediFind in the treatment of Gastroesophageal Junction Cancer. He is also highly rated in 12 other conditions, according to our data. His top areas of expertise are Stomach Cancer, Gastroesophageal Junction Cancer, Renal Oncocytoma, and Colorectal Cancer.

View Profile
EV
Eric D. Van Cutsem
Eric D. Van Cutsem
Elite
Highly rated in
26
conditions

KU Leuven University Of Leuven

BE 

Eric Van Cutsem is in Belgium. Van Cutsem is rated as an Elite expert by MediFind in the treatment of Gastroesophageal Junction Cancer. He is also highly rated in 26 other conditions, according to our data. His top areas of expertise are Gastroesophageal Junction Cancer, Pancreatic Cancer, Stomach Cancer, and Colorectal Cancer.

View Profile
 
 
 
 
Learn about our expert tiers
Learn more
YJ
Dr. Yelena Y. Janjigian
Hematology Oncology | Hematology | Oncology
Elite
Highly rated in
7
conditions
Hematology Oncology
Hematology
Oncology

Memorial Sloan Kettering Cancer Center

1275 York Ave 
New York, NY 10065

Yelena Janjigian is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Janjigian has been practicing medicine for over 19 years and is rated as an Elite doctor by MediFind in the treatment of Gastroesophageal Junction Cancer. She is also highly rated in 7 other conditions, according to our data. Her top areas of expertise are Gastroesophageal Junction Cancer, Stomach Cancer, Esophageal Cancer, and Renal Oncocytoma. She is licensed to treat patients in New York. Dr. Janjigian is currently accepting new patients.

View Profile
View All Doctors
What are the Latest Advances for Gastroesophageal Junction Cancer?
Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: a single-arm, phase 2 study.
Condition: Elderly Chinese Patients with Advanced Gastric or Gastroesophageal Junction Cancer (G/GEJ)
Journal: BMC cancer
Treatment Used: Biweekly Oxaliplatin Plus S1
Number of Patients: 42
Published: March 10, 2022
View publication
Summary: Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: a single-arm, phase 2 study.
A Rare Case of Primary Splenic Malignant Lymphoma Associated with Esophagogastric Junction Neuroendocrine Carcinoma(NEC).
Condition: Primary Splenic Malignant Lymphoma Associated with Esophagogastric Junction Neuroendocrine Carcinoma (NEC)
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Treatment Used: Surgery and Adjuvant Chemotherapy
Number of Patients: 1
Published: March 06, 2022
View publication
Summary: A Rare Case of Primary Splenic Malignant Lymphoma Associated with Esophagogastric Junction Neuroendocrine Carcinoma(NEC).
Tired of the same old research?
Check Latest Advances
Preoperative Esophageal Decompression and Enteral Nutrition Using a W-ED Tube in Patients with Esophagogastric Junction Cancer-A Case Report.
Condition: Esophagogastric Junction Cancer
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Treatment Used: Preoperative Esophageal Decompression and Enteral Nutrition Using a W-ED Tube
Number of Patients: 1
Published: January 19, 2022
View publication
Summary: Preoperative Esophageal Decompression and Enteral Nutrition Using a W-ED Tube in Patients with Esophagogastric Junction Cancer-A Case Report.
View All Latest Advances
What are the latest Gastroesophageal Junction Cancer Clinical Trials?
A Phase 1b Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-103)
Status: Recruiting
Start Date: May 17, 2022
Intervention Type: Drug
Study Drugs: Nivolumab, Oxaliplatin, Capecitabine
Phase: Phase 1
View Trial
Summary: The main objective of this study is to evaluate the safety and tolerability of bemarituzumab in combination with other anti-cancer therapies.
Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1/2 Study of Olaparib in Combination With Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)
Who is this study for: Patients with metastatic or locally recurrent gastric or gastroesophageal junction cancer that cannot be removed by surgery
Status: Active, not recruiting
Start Date: November 7, 2017
Intervention Type: Biological, Drug
Study Drugs: Ramucirumab, Paclitaxel, Olaparib
Phase: Phase 1/Phase 2
View Trial
Summary: This phase I/II trial studies the side effects and best dose of olaparib when given together with ramucirumab and how well they work in treating patients with gastric or gastroesophageal junction cancer that has spread to other places in the body (metastatic), has come back (recurrent), or cannot be removed by surgery (unresectable). Olaparib may stop the growth of tumor cells by blocking some of ...
View All Clinical Trials